Home
overview

SAE Media Group’s 14th Annual Conference
RNA Therapeutics
8-9 February 2023 | London, UK
-------------------------------------------------------------------------
SAE Media Group is proud to announce the 14th Annual RNA Therapeutics Conference taking place on 8-9 February 2023

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. With Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field.

In 2023, we will see the return of SAE’s RNA Therapeutics conference to a live in-person event, showcasing an update on mRNA therapeutic applications, coupled with an industry outlook of the field. We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA. Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more.

Don't miss this opportunity to network with the pharma and biotech community of global experts in the UK and Europe; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.
 

  • Explore how mRNA is leading the way in the genetic medicine space as the next generation of novel drug modalities
  • Investigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics
  • Enhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech, Neuway Pharma and Ethris GmbH
  • Engage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory, neurodegenerative, and infectious diseases
     

Pharma and Biotech Directors, Managers and Heads of Departments of:
• RNA
• Genetic Medicine
• Oligonucleotide Discovery
• RNA Discovery
• New Modalities
• RNA Biology
• RNA Formulation and Delivery
• Targeted Delivery
• Clinical Development
• Pre-Clinical Development
• Oligonucleotide Chemistry
• Drug Discovery
• Target Discovery
• Medicinal Chemistry
• RNA Development
• RNA Vaccines
• RNA Biochemistry
 

AlgiPharma AS; ARNAY Sciences; AstraZeneca; AstraZeneca R&D; Avidity Biosciences; BIA Separations; BioNTech; BIORCHESTRA Co., Ltd.; CAMP4 Therapeutics; Cardior Pharmaceuticals; Chiesi Farmaceutici spa; Coalition for Epidemic Preparedness Innovations (CEPI); Cytiva; Duke University; Eli Lilly and Company; Envisagenics; Envisagenics Inc; Envisagnics, Inc; eTheRNA Immunotherapies NV; Evox Therapeutics Ltd; GSK; HAYA Therapeutics; Imperial College London; Imperial College London and MiNA Therapeutics ; InteRNA Technologies BV; Ioinis Pharma; Ionis Pharmaceuticals Inc.; Janssen Pharmaceutical Companies of Johnson & Johnson; Janssen Pharmaceuticals; Locanabio; mCureX Therapeutics; MHRA; Micropore Technologies Ltd; Miescher Pharma GmbH; MiNA Therapeutics; NNE A/S; OilX Pharmaceuticals; OliX US; Oost NL; Polyplus-Transfection; Purolite International Ltd; ReCode Therapeutics; Roche Diagnostics Deutschland; Roche Diagnostics Deutschland GmbH; Roche Innovation Center Copenhagen; Roche Products Ltd; Royal College of Surgeons in Ireland; Sartorius AG; Sirnaomics, Inc; Stoke Therapeutics; Stoke Therapeutics Inc; Teknova; Thermofisher Scientific; TranSINE Therapeutics; University College London; Vernagen LLC;

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Developing Oligonucleotides into Therapies: Opportunities and Challenges

Shalini Andersson

Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
View Bio

  • Introduction to oligonucleotide therapeutics and the current landscape
  • Therapeutic promise of oligonucleotide modalities
  • Outlining some of the key challenges in oligonucleotide therapeutics including extra-hepatic delivery
  • Exploring some of the emerging delivery solutions and future opportunities
  • 9:50 An industry outlook on the current RNA landscape

    Arun Kumar

    Arun Kumar, Preclinical Lead Vaccine Development, Coalition for Epidemic Preparedness Innovations (CEPI)
    View Bio

  • Recent developments in RNA technologies
  • Ones to watch: what are the most exciting opportunities in the RNA space?
  • Challenges facing the RNA therapeutic space in the coming years
  • 10:30 Morning Coffee

    11:00 Tailoring delivery systems for next generation mRNA therapeutics

    Heinrich Haas

    Heinrich Haas, VP Formulation & Drug Delivery, BioNTech
    View Bio

  • Nanoparticle technologies for nucleotide and drug delivery systems
  • Structural and functional coherencies within selected delivery systems
  • Novel approaches and tailored solutions for future mRNA therapeutics
  • 11:40 mRNA Delivery to the CNS: Targeting Neurological Disease

    Oliver Ernst

    Oliver Ernst, Managing Director, NEUWAY Pharma GmbH
    View Bio

  • EnPC® as drug delivery technology providing for treatment of multiple disorders delivering a broad range of therapeutic modalities
  • Discussion of utilising naturally derived protein capsules to deliver mRNA across the blood brain barrier and resulting benefits
  • Exploring the development of innovative therapeutics for treatment of brain diseases and CNS-related genetic diseases
  • Future opportunities in the targeted delivery of RNA therapeutics
  • 12:20 Session Reserved for eTheRNA

    13:00 Networking Lunch

    14:00 Exploring mRNA therapeutics in the treatment of chronic lung diseases

    Christian Plank

    Christian Plank, Chief Technology Officer, Ethris GmbH
    View Bio

  • Utilising mRNA for protein replacement therapies in respiratory and infectious diseases
  • Reviewing lipidoid nanoparticle formulation technologies
  • Caste study: SNIM RNA as a novel therapeutic platform
  • 14:40 The therapeutic potential of mRNA in the restoration of endothelial cell function

    Daniel Tondera

    Daniel Tondera, Head of Biology, Pantherna Therapeutics GmbH
    View Bio

  • Exploring Next-generation PTX_LNP™ formulations for delivering PTXmRNA™ to various tissues and cell types
  • Reviewing PTXcLNP™ enabling target protein expression in the vascular endothelium of the lung via the intravenous delivery
  • Case study: mRNA therapy to prevent lung oedema in Acute Respiratory Distress Syndrome
  • 15:20 Optimizing RNAi applications through novel AI technologies

    Yaniv Erlich

    Yaniv Erlich, CEO, Eleven Therapeutics
    View Bio

  • Utilising massively parallel combinatorial searches and AI algorithms to unleash the full power of RNAi
  • Reviewing the structure-activity relationship (SAR) of RNAi molecules to enhance drug safety and efficacy
  • Developing the next generation of RNAi therapeutics to silence the disease-causing genes

     

  • 16:00 Afternoon Tea

    16:30 AI/ML developed RNA therapeutics for neurodegenerative diseases

    Martin Akerman

    Martin Akerman, Chief Technical Officer, Envisagenics
    View Bio

  • Overcoming in-silico modeling challenges for neurodegenerative diseases
  • How Envisagenics’ SpliceCore platform can be used in designing antisense oligonucleotides
  • Translational R&D from in-silico to in-vitro for potential ASO candidates in neurodegenerative diseases
  • 17:10 Role of Clinical Pharmacology in the Development of Novel RNA Modalities

    Venkatesh Pilla Reddy

    Venkatesh Pilla Reddy, Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca
    View Bio

  • Delving into model informed therapeutic development for novel therapies including self-amplifying RNA technology
  • Reviewing application and benefi ts of Clinical Pharmacology in AAV, mRNA and self-amplifying RNAs based therapies
  • Next steps: assessing the current fi eld and future work required for approval of novel RNA vaccines and immunotherapies
  • 17:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    9:10 Host-directed immunotherapy and antiviral therapies using RNA therapeutics: perspectives and challenges in Drug Discovery Research

    Souphalone Luangsay

    Souphalone Luangsay, Senior Principal Scientist, F. Hoffmann-La Roche Ltd

  • Identification and target assessment of host –virus interactions using antisense oligonucleotides (ASOs)
  • Challenges during lead identification and optimization process: profiling the ideal compound to become a clinical candidate
  • ASO pharmacology translatability
  • 9:50 Exploring Extracellular Vesicles as delivery agents for RNA therapeutics

    Virginia Castilla-Llorente

    Virginia Castilla-Llorente, Associate Director, Evox Therapeutics Ltd
    View Bio

  • An introduction into the therapeutic potentials of Extracellular Vesicles
  • Advancing the RNA therapeutic landscape through the Evox platform for mRNA, siRNA, and gene editing EV delivery
  • Future perspectives: next steps in the development of EVs for the delivery of RNA modalities
  • 10:30 Morning Coffee

    11:00 OligoPhore and SemaPhore for extrahepatic delivery of therapeutic RNA

    Covadonga Paneda

    Covadonga Paneda, Chief Development Officer, Altamira Therapeutics
    View Bio

  • Description of OligoPhore and SemaPhore platforms for delivery therapeutic RNA
  • Rapid and extensive pH-dependent release of RNA from endosomal resulting in effective delivery into cells
  • Distribution of therapeutic RNA into extrahepatic tissues
  • Examples of effective RNA activity in animal models of disease
  • 11:40 Genetic medicine: state of the art, frontiers and current research

    Joseph Martinelli

    Joseph Martinelli, Executive Director, Eli Lilly

  • Addressing key challenges at the forefront of the next generation of genetic medicines
  • The role of Nucleic acid innovation in the development of RNA therapeutics
  • Exploring delivery innovation as a crucial component in the advancement of RNA therapies
     
  • 12:20 Advancing RNA therapeutics through the development of long non-coding

    Samir Ounzain

    Samir Ounzain, CEO, HAYA Therapeutics
    View Bio

  • Exploring new directions in the identification of novel lncRNA targets
  • Reviewing antisense oligonucleotides in the targeting of disease generating lncRNAs
  • Case study: targeting the lncRNA Wisper, a cardiac tissue-enriched driver of fibrosis in the heart
  • 13:00 Networking Lunch

    14:00 Panel Discussion: Advancing RNA therapeutics by improving drug-like properties of RNA modalities

  • Upcoming RNA-based medicines beyond vaccines: What will be the next products? What should industry be looking to work on?
  • Delivery systems beyond LNPs: Will LNPs do the job or do we need more for targeted delivery, such as: extrahepatic and organ-specific delivery, BBB and tumours?
  • Types of RNA: What are the emerging ‘flavors’ and what is promising - saRNA, modRNA, circularRNA?
  • Ekkehard Leberer

    Ekkehard Leberer, Life Sciences Consultant, Elbicon
    View Bio

    Heinrich Haas

    Heinrich Haas, VP Formulation & Drug Delivery, BioNTech
    View Bio

    Dmitry Samarsky

    Dmitry Samarsky, Chief Technology Officer, Sirnaomics, Inc
    View Bio

    Christian Plank

    Christian Plank, Chief Technology Officer, Ethris GmbH
    View Bio

    Shalini Andersson

    Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
    View Bio

    14:40 Novel RNA modulating therapies for the treatment of genetic neurological diseases

    Nicole Datson

    Nicole Datson, Chief Development Officer, Vico Therapeutics
    View Bio

  • Delving into the therapeutic benefits of targeting RNA modulation using antisense oligonucleotides
  • Exploring the scalability of the VICOMER technology, including future disease targets and potential challenges
  • Case study – VO659 targeting polyglutamine disorders, spinocerebellar ataxia type 3 and type 1 and Huntington’s disease
  • 15:20 Targeted RNA therapeutics approaches for developing transformational medicines for patients

    Tamar Grossman

    Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson
    View Bio

  • RNA modalities for therapeutics and vaccine development
  • Novel carriers for improved extra-hepatic targeting
  • CNS delivery of siRNA for neurological disease therapies
  • 16:00 Afternoon Tea

    16:30 GalAhead™: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes

    Dmitry Samarsky

    Dmitry Samarsky, Chief Technology Officer, Sirnaomics, Inc
    View Bio

  • Sirnaomics has developed novel proprietary GalNAc-RNAi therapeutic platform – GalAhead™
  • GalAhead comprises two key technological components – mxRNA™ (miniaturized RNAi triggers) and muRNA™ (multi-unit RNAi triggers)
  • mxRNAs are composed of single ~30 nt long oligonucleotides to downregulate individual genes
  • muRNAs are comprised of multiple oligonucleotides (2 or more) to simultaneously silence two or more targets
  • Data will be presented validating these two technologies both in vivo and in vitro, as well as progress report on quickly expanding GalAhead therapeutic pipeline
     
  • 17:10 Developing siRNAs as the next generation of RNA therapies

    Ying Yu

    Ying Yu, Associate Director, AbbVie
    View Bio

  • Delving into siRNAs lacking imunostimulatory properties and what this means for drug target validation
  • Expanding on siRNA-mediate cleavage assay development
  • Analysing siRNA efficacies and pharmacokinetics
  •  Case study: siRNA pre-clinical toxicology and immunogenicity data
  • 17:50 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Arun Kumar

    Arun Kumar

    Preclinical Lead Vaccine Development, Coalition for Epidemic Preparedness Innovations (CEPI)
    Christian Plank

    Christian Plank

    Chief Technology Officer, Ethris GmbH
    Covadonga Paneda

    Covadonga Paneda

    Chief Development Officer, Altamira Therapeutics
    Daniel Tondera

    Daniel Tondera

    Head of Biology, Pantherna Therapeutics GmbH
    Dmitry Samarsky

    Dmitry Samarsky

    Chief Technology Officer, Sirnaomics, Inc
    Ekkehard Leberer

    Ekkehard Leberer

    Life Sciences Consultant, Elbicon
    Heinrich Haas

    Heinrich Haas

    VP Formulation & Drug Delivery, BioNTech
    Joseph Martinelli

    Joseph Martinelli

    Executive Director, Eli Lilly
    Martin Akerman

    Martin Akerman

    Chief Technical Officer, Envisagenics
    Nicole Datson

    Nicole Datson

    Chief Development Officer, Vico Therapeutics
    Oliver Ernst

    Oliver Ernst

    Managing Director, NEUWAY Pharma GmbH
    Samir Ounzain

    Samir Ounzain

    CEO, HAYA Therapeutics
    Shalini Andersson

    Shalini Andersson

    Vice President Oligonucleotide Discovery, AstraZeneca
    Souphalone Luangsay

    Souphalone Luangsay

    Senior Principal Scientist, F. Hoffmann-La Roche Ltd
    Tamar Grossman

    Tamar Grossman

    Vice President, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson
    Venkatesh Pilla Reddy

    Venkatesh Pilla Reddy

    Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca
    Virginia Castilla-Llorente

    Virginia Castilla-Llorente

    Associate Director, Evox Therapeutics Ltd
    Yaniv Erlich

    Yaniv Erlich

    CEO, Eleven Therapeutics
    Ying Yu

    Ying Yu

    Associate Director, AbbVie

    Arun Kumar

    Preclinical Lead Vaccine Development, Coalition for Epidemic Preparedness Innovations (CEPI)
    Arun Kumar

    Dr. Arun Kumar is the Preclinical Vaccines Development Lead at the Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway. The main objective of CEPI is to accelerate the development of vaccines against emerging/re-emerging infectious diseases and enable access to these vaccines for people during outbreaks. Dr. Kumar previously held positions at the GlaxoSmithKline Vaccines & Novartis Vaccines and Diagnostics, where he led vaccine development programs based on the mRNA technology. At CEPI, Dr. Kumar is leading programs focusing on mRNA innovations, preclinical vaccine development and co-leading CEPI Centralized Global Laboratory Network.
    Dr. Kumar holds a Ph.D. in Viral Immunology and Infectious diseases from the University of Helsinki, Finland.
     

    Christian Plank

    Chief Technology Officer, Ethris GmbH
    Christian Plank

    Christian Plank is co-founder and chief technology officer of Ethris GmbH which is located in the Munich metropolitan area in Germany. Christian Plank holds a PhD in biochemistry from the University of Vienna, Austria. After a postdoctoral fellowship with Prof. Francis C. Szoka at the University of California, San Francisco, he returned to Europe to become a professor at the Technical University of Munich, Germany. He has been principal investigator and coordinator of numerous grant projects that have focused on non-viral nucleic acid delivery and nanomagnetic drug targeting. He is the author of more than 170 publications and co-inventor of numerous patents in the field of nucleic acid delivery.

    Covadonga Paneda

    Chief Development Officer, Altamira Therapeutics
    Covadonga Paneda

    Covadonga Pañeda, Ph.D. has over 15 years of experience in leadership and management of biotechnology companies. Before joining Altamira in April 2022, she spent seven years managing Sylentis’ R&D efforts, a clinical stage RNAi company, two years leading the translational activities of start-up companies Isquaemia Biotech and Mirnax Biosens; and most recently, she served as Director of Development at LiMM Therapeutics, a French neuroimmune biopharmaceutical company.
    Dr. Pañeda holds a Ph.D. in Biochemistry and Molecular Biology from the Faculty of Medicine at Universidad Autónoma, Madrid, Spain, and a Master in Management of Biotechnology Companies awarded by Fundación Genoma España, Madrid, Spain.
     

    Daniel Tondera

    Head of Biology, Pantherna Therapeutics GmbH
    Daniel Tondera

    Daniel Tondera is an experienced expert in the field of RNA based therapeutics.
    Before joining Pantherna Therapeutics, he was Group Leader at Silence Therapeutics where he was investigating the potential of using miRNAs and mRNA-based gene editing technologies for systemic LNP-mediated therapies. Prior to this he held positions as Group Leader at Cenix Bioscience in Dresden/Germany and as Senior Scientist at CRT in London/UK.
    Daniel studied biochemistry at the University of Potsdam/Germany and received his PhD from the University of Potsdam in collaboration with Silence Therapeutics followed by postdoctoral training at the University of Geneva/Switzerland and at the Dana-Farber-Cancer Institute in Boston/MA.
     

    Dmitry Samarsky

    Chief Technology Officer, Sirnaomics, Inc
    Dmitry Samarsky

    Dmitry Samarsky, PhD has been at the inception of RNAi technology and drug development - starting in 2001 as Director of Technology Development at Sequitur (acquired by Invitrogen) and (in 2005) as Director of Technology Development at Dharmacon (now part of GE). He then served as VP of Technology Development at RXi Pharmaceuticals, USA (2007-2011), SVP of Technology and International Business Development at RiboBio, China (2011-2016) and, most recently, as Chief Scientific Officer at Silence Therapeutics, Germany/UK (2016-2018). Dr. Samarsky has authored more than 40 scientific papers, articles, book chapters, patents, and patent applications. He has been an invited speaker at more than 100 international conferences, and currently serves on the Scientific Advisory Boards for the OTS (Oligonucleotide Therapeutics Society). Dr. Samarsky received his doctorate in biochemistry and molecular biology from University of Massachusetts, Amherst (1998), followed by a postdoctoral position as an H. Arthur Smith Fellow for Cancer Research in Michael Green's lab at University of Massachusetts Medical School (1998-2001).

    Ekkehard Leberer

    Life Sciences Consultant, Elbicon
    Ekkehard Leberer

    Ekkehard serves as an independent life sciences consultant at ELBIOCON (www.elbiocon.com) with more than 30 years of experience in biotechnology and pharmaceutical industry. He headed research teams and held managerial positions at the Biotechnology Research Institute of the National Research Council (NRC) of Canada in Montreal and in Big Pharma at Hoechst Marion Roussel, Aventis and Sanofi in Martinsried/Munich and Hoechst/Frankfurt. He was educated in chemistry and molecular biology at the University of Konstanz (Ph.D. and Habilitation in biochemistry) and University of Toronto (PostDoc at the Banting and Best Department of Medical Research). He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.
    His scientific and managerial activities included responsibilities in functional genomics, genetic engineering, biological sciences, pre-clinical and clinical development of various therapeutic modalities encompassing small molecule drugs and biopharmaceuticals (peptides, antibodies, oligonucleotides, and mRNAs), drug delivery, portfolio management, external innovation, alliance management and business strategies.
    Ekkehard served as a member in Scientific Advisory Boards of several biotechnology companies, and he was the Head of the Supervisory Board of BioM, Munich (www.bio-m.org). He is a member in the life sciences consulting network NewGuide (www.newguide.net).
     

    Heinrich Haas

    VP Formulation & Drug Delivery, BioNTech
    Heinrich Haas

    Heinrich Haas
    Vice President RNA Formulation & Dug Delivery
    BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz, Germany

    Heinrich has his professional focus on development of pharmaceutical products in the field of nanotechnology and drug & RNA delivery. In his Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz and academic career in Italy and Brazil he researched lipid membranes and organized bio-molecular systems. Having moved to pharmaceutical industry he developed nanoparticle products with application in cancer, inflammatory diseases autoimmune diseases and other indications. At BioNTech, he is the scientific lead of the formulation and analytics department, which develops RNA therapeutics based on a broad scope of delivery technologies..
     

    Joseph Martinelli

    Executive Director, Eli Lilly
    Joseph Martinelli

    Martin Akerman

    Chief Technical Officer, Envisagenics
    Martin Akerman

    Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.

    Nicole Datson

    Chief Development Officer, Vico Therapeutics
    Nicole Datson

    Nicole Datson has held the position of Chief Development Officer at VICO Therapeutics since the company was founded in 2019. Prior to joining VICO, she served as Senior Director Drug Discovery and Early Preclinical Development at BioMarin Nederland and was head of preclinical development at Prosensa Therapeutics. She has more than a decade of expertise in developing antisense oligonucleotide-based therapies for neuromuscular and neurodegenerative genetic disorders and has headed VICO’s VO659 programme from early R&D through nonclinical safety studies to the first clinical trial.
    She obtained her PhD in molecular genetics at Leiden University.
     

    Oliver Ernst

    Managing Director, NEUWAY Pharma GmbH
    Oliver Ernst

    Dr. Ernst is CEO and Managing Director of NEUWAY Pharma. Oliver joined NEUWAY in November 2018 as Managing Director, leading business development, strategic partnering and financing, with strong background in management of innovation and intellectual property. Prior to NEUWAY, Oliver had gained over ten years of professional experience in the field of intellectual property and innovation management ranging from private practice to large enterprise. Oliver graduated with a degree in biotechnology engineering from the Technical University Berlin and received his PhD at the Fraunhofer Institute for Biomedical Engineering, Potsdam (IBMT).

    Samir Ounzain

    CEO, HAYA Therapeutics
    Samir Ounzain

    Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease. Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.

    Shalini Andersson

    Vice President Oligonucleotide Discovery, AstraZeneca
    Shalini Andersson

    Shalini is Vice President Oligonucleotide Discovery in BioPharmaceuticals R&D, AstraZeneca. She is a member of the Management Team for Discovery Sciences as well as of the Review Board for drug projects in all therapy areas in BioPharmaceuticals R&D.
    Shalini is also leading Targeted Drug Delivery within Cardiovascular, Renal and metabolic diseases and several collaborations with academic research groups and biotechs in the nucleic therapeutics field.
    Shalini received her PhD in 1989 at the University of Linköping, Sweden. Prior to joining AstraZeneca in 1997, she was Associate Professor in Organic and Analytical Chemistry at the University of Linköping, Sweden. She is the author or co-author of over 60 peer reviewed articles and 5 patents.
    Shalini is member of several boards including the Board of Oligonucleotide Therapeutics Society, the Member of Board of Directors for OligoNova, the Swedish national center for research and development of therapeutic oligonucleotides and of the Scientific Advisory Group for Nucleic Acid Therapy Accelerator (NATA, UK).
     

    Souphalone Luangsay

    Senior Principal Scientist, F. Hoffmann-La Roche Ltd
    Souphalone Luangsay

    Tamar Grossman

    Vice President, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson
    Tamar Grossman

    Dr. Tamar Grossman is a VP and Global Head of RNA and Targeted Therapeutics at Johnson and Johnson. Tamar is responsible for the delivery of RNA based development candidates and ADCs across all therapeutic areas. Previously, she was a Senior Director and Head of Rare Diseases at Arcturus Therapeutics where she developed RNA therapeutics across different RNA modalities. Prior to Arcturus, Tamar was the Director of Translational Medicine at Ionis Pharmaceuticals where she led various antisense oligonucleotide research programs to clinical development. She received her PhD in Biochemistry from Tel-Aviv University and complete postdoctoral research training at the UCSD.

    Venkatesh Pilla Reddy

    Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca
    Venkatesh Pilla Reddy

    Dr. Venkatesh Pilla Reddy, PhD is Director, Clinical Pharmacology and Quantitative Pharmacology function of AstraZeneca, Cambridge UK. He is currently supporting COVID-19 Projects (AZ Vaccine and EVUSHELD) as a Global Clinical Pharmacology Lead. He obtained his PhD in Pharmacometrics through a unique industry collaboration program between Pfizer, Janssen Pharmaceuticals and Merck via TI Pharma in the Netherlands. His PhD work was focused on PKPD M&S of antipsychotic drugs. He subsequently worked at Quantitative Pharmacology and Pharmacometrics group in Merck & Co before joining AstraZeneca Early Oncology function. Venkatesh provided Model-Informed Drug Development support to various oncology projects. He has been influential in gaining acceptance and addressing questions from regulatory agencies for EVUSHELD (Tixagevimab and Cilgavimab), Olaparib and Osimertinib programs. He has participated on MIDD related panel discussion with the European Medicines Agency and the US Food and Drug Administration (FDA). Venkatesh currently holds the Deputy Topic Leader position at the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Management Committee to work on the ICH M12 DDI guidelines, and co-leads various cross-industry working groups such as IQ TALG, ISOP and ISSX M&S. Over 20 years of his industry carrier, he has published > 60 peer review research articles, 2 book chapters.

    Virginia Castilla-Llorente

    Associate Director, Evox Therapeutics Ltd
    Virginia Castilla-Llorente

    Virginia has over 13 years of experience working in RNA, first as an academic from a more basic research approach, and, for the last 5 years, in biotech, as Research Associate Director in Evox Therapeutics. Prior to this, Virginia did a postdoc studying miRNA mediated gene silencing in Memorial Sloan Kettering Cancer Centre, followed by a second postdoc focused on the understanding of protein-mRNA interactions in UCL and The Francis Crick Institute. Virginia has authored a number of scientific publications and patents on the aforementioned fields. Virginia earned her PhD in Molecular Biology in Centro de Biologia Molecular Severo Ochoa, UAM.

    Yaniv Erlich

    CEO, Eleven Therapeutics
    Yaniv Erlich

    Dr. Yaniv Erlich is the co-founder and CEO of Eleven Therapeutics. Prior to this position, he was the CSO of MyHeritage, a consumer genomics company (acquired by Francisco Partners), an Associate Professor of Computer Science at Columbia University and a Principal Investigator at the Whitehead Institute, MIT. Dr. Erlich received his bachelor’s degree from Tel-Aviv University, Israel (2006) and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory (2010). Dr. Erlich’s research interests are computational human genetics. Dr. Erlich is a TEDMED speaker (2018), the recipient of DARPA’s Young Faculty Award (2017), the Burroughs Wellcome Career Award (2013), Harold M. Weintraub award (2010), the IEEE/ACM-CS HPC award (2008), and he was selected as one of 2010 Tomorrow’s PIs team of Genome Technology.

    Ying Yu

    Associate Director, AbbVie
    Ying Yu

    Over 25 years of research experiences in pharmaceutical companies and academic institutions with focus on RNA therapeutics, ophthalmic drug discovery and vascular physiology.

    Expertise in small interference RNA (siRNA)-based drug target validation and RNA therapeutics. including 1) Selection of siRNAs lacking immunostimulatory properties; 2) in vivo siRNA-mediated cleavage assay development; 3) in vivo siRNA efficacy evaluation and 4) in vivo siRNA PK/PD assay development.
    Two patents on novel gene discovery and siRNA delivery, awarded 4-year research grant from American heart association, two book chapters, several national awards, and over 30 papers in peer-reviewed journals including Nature, PNAS, Circulation and J Immunology.
     

    Sponsors

    Exhibitors

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Short Conference Agenda

    Download

    Full Conference Agenda

    Download

    RNA Therapeutics 2023 Brochure

    Download

    Speaker Biographies

    Download

    Conference Chair Invitation Letter - Heinrich Haas, BioNTech

    Download

    Sponsors


    eTheRNA

    Sponsors
    http://www.etherna.be

    eTheRNA is an mRNA technology platform company with integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and manufacturing customized lipid nanoparticles (cLNP) formulations tailored for the prevention and treatment of various pathological states, providing end-to-end solutions for next generation mRNA therapeutics. The company believes that customized LNPs are critical enablers in advancing mRNA technologies to new levels of prophylactic and therapeutic utility.



    Roche

    Sponsors
    https://custombiotech.roche.com/global/en/portfolio/mrna-therapeutics-raw-materials.html

    Roche CustomBiotech - We provide reliable, tailor-made and high-quality raw materials, kits and technologies to biopharma and diagnostics companies.

    With the CustomBiotech division Roche merged its innovative technologies, excellent knowledge, and decades of experience in the Biopharma and Diagnostics Industry. We work with many pioneering mRNA companies to develop and manufacture needed raw material solutions meeting the strict requirements in Biopharma. Our guiding tenet is to minimize variation of products built on our raw materials by ensuring excellent quality, high performance within narrow tolerances, and reliable delivery.



    Sartorius BIA Separations d.o.o.

    Sponsors
    https://www.biaseparations.com/

    Sartorius BIA Separations, develops and manufactures market leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids, and mRNA, which are applied in cell and gene therapies. Sartorius BIA’s Cornerstone® Biomanufacturing Development Services are result of more than 20 years of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production, while improving the safety of therapeutic products. Sartorius BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics; Sartorius BIA Separations also has a keen presence with novel drug candidates in the clinical pipeline.


    Exhibitors


    PolyPeptide

    Exhibitors
    http://www.polypeptide.com/

    PolyPeptide is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India with around 1,200 employees as per the middle of 2022. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.



    Symbiosis Pharmaceutical Services

    Exhibitors
    https://www.symbiosis-pharma.com/

    Symbiosis Pharmaceutical Services is a contract development and manufacturing organisation (CDMO) specialising in the GMP manufacture and sterile fill/finish of vials for clinical trials and commercial supply. Regulatory compliance, technical capability and operational flexibility are at its core.

    Manufacturing from a purpose-built FDA inspected and MHRA-licensed facility, the CDMO can handle products that require aseptic liquid filling and lyophilisation for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs.

    Offering fast access to manufacturing slots and accelerated release of drug product, Symbiosis is primed to meet demand for small-scale, fast-turnaround drug product sterile manufacturing.


    Media Partners


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Gene Therapy Net

    Supporters
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Genomeweb L L C

    Supporters
    http://www.genomeweb.com

    GenomeWeb LLC is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.

    GenomeWeb’s editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics.

    GenomeWeb readers can be found in major biopharmaceutical companies, top research universities, biomedical institutes, and government laboratories.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    On Drug Delivery

    Supporters
    http://www.ondrugdelivery.com/subscribe

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out